Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards
Check out the full list of winners at The Gazette.|
Helping small businesses create jobs
Rep. Chris Van Hollen has written an Op-Ed in Politico about his efforts to help small businesses like Sanaria create good, quality jobs in Maryland. Read the full story!|
Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial
Read the new publication in PLOS ONE.
Abstract
Background
Experimental infection of malaria-naïve volunteers by the bite of Plasmodium falciparum-infected mosquitoes is a preferred means to test the protective effect of malaria vaccines and drugs. The standard model relies on the bite of five infected mosquitoes to induce malaria. We examined the efficacy of malaria transmission using mosquitoes raised aseptically in compliance with current Good Manufacturing Practices (cGMPs).
Methods and Findings
Eighteen adults aged 18–40 years were randomized to receive 1, 3 or 5 bites of Anopheles stephensi mosquitoes infected with the chloroquine-sensitive NF54 strain of P. falciparum.
Seventeen |
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria’s PfSPZ vaccine
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine.
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University.
Plasmodium yoelii-Infected A. stephensi Inefficiently Transmit Malaria Compared to Intravenous Route
Read the full publication in PLOS ONE.
Abstract
It was recently reported that when mosquitoes infected with P. berghei sporozoites feed on mice, they deposit approximately 100–300 sporozoites in the dermis. When we inoculate P. yoelii (Py) sporozoites intravenously (IV) into BALB/c mice, the 50% infectious dose (ID50) is often less than 3 sporozoites, indicating that essentially all Py sporozoites in salivary glands are infectious. Thus, it should only take the bite of one infected mosquito to infect 100% of mice. In human subjects, it takes the bite of at least 5 P. falciparum-infected mosquitoes to achieve 100% blood |
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria
Read the full paper as published in Human Vaccines.
Abstract
Immunization of volunteers by the bite of mosquitoes carrying radiation-attenuated Plasmodium falciparum sporozoites protects greater than 90% of such volunteers against malaria, if adequate numbers of immunizing biting sessions and sporozoite-infected mosquitoes are used. Nonetheless, until recently it was considered impossible to develop, license and commercialize a live, whole parasite P. falciparum sporozoite (PfSPZ) vaccine. In 2003 Sanaria scientists reappraised the potential impact of a metabolically active, non-replicating PfSPZ vaccine, and outlined the challenges to producing such a vaccine. Six years later, significant progress has been made in overcoming |
Dr. David Dolberg, Sanaria’s Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer
Sanaria Inc. is proud to recognize and celebrate the role of Dr. David Dolberg, Esq. ‐ Sanaria’s intellectual property attorney ‐ in helping to shape current approaches to the understanding and treatment of cancer. Prior to launching a career in law, David was a postdoctoral fellow in the laboratory of Dr. Mina Bissell at Berkeley, who was recently highlighted in a New York Times article by Gina Kolata, “Old Ideas Spur New Approaches in Cancer Fight” (December 29, 2009).
The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication of Malaria
Read the full article in the Journal of Infectious Diseases.
There has been a recent call for global malaria eradication. The prospects of achieving this ambitious goal are diminished by the limited tool set now available—notably, the lack of a licensed malaria vaccine. This is in large part because the multistage Plasmodium parasites that cause malaria have a much more complex life cycle and larger genomes than do the viruses that cause smallpox and polio, the only infectious agents that have been completely or nearly eradicated from the world by vaccines. We think that (1) vaccines could play as |
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million.
Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him
Some people will go to extreme lengths to avoid mosquito bites. They'll wear long sleeves and pants in the heat of summer, surround themselves with citronella candles and torches, and spray foul-smelling chemicals all over their bodies—or simply not set foot outside when they know the bugs are biting. Stephen Hoffman isn't quite like those people.
Pulling malaria from mosquitoes to fight disease
Think your job's tedious? Try beheading 100 mosquitoes an hour. Gently, no smushing allowed. Malaria parasites lurk in these mosquitoes' salivary glands, and a small company on the outskirts of the nation's capital needs them unharmed for a dramatic test - attempting the first live vaccine to fight malaria.
Malaria Vaccine Developer, Sanaria Inc., receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.
Phase 1 trial of whole-parasite malaria vaccine to begin
FDA approval for testing in humans watershed moment for unique malaria vaccine approach
ROCKVILLE, Maryland – In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland- based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial—the first tests in adult volunteers—of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria’s approach deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.
Having met the US Food and Drug Administration’s (FDA) |
Physician leads efforts to rid world of malaria
In an interview with the student newspaper for the University of Georgia, Sanaria's Dr. Stephen Hoffman discusses his efforts to develop a malaria vaccine.
The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine
We are developing a radiation attenuated Plasmodium falciparum sporozoite (PfSPZ) malaria vaccine. An important step was to determine the minimum dose of irradiation required to adequately attenuate each sporozoite. This was studied in the Plasmodium yoelii rodent model system. Exposure to 100 Gy completely attenuated P. yoelii sporozoites (PySPZ).
Sanaria and Sanaria’s CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
In the December, 2008 issue of Esquire, read the great discussion of malaria and the critical, innovative work that Sanaria is doing to develop new vaccines.
Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites
Every day 2000 children die from malaria in Africa alone. The infec6on is transmi9ed from human to human by bi6ng mosquitoes and remains one of the world’s most devasta6ng diseases. Despite many years of effort a vaccine is s6ll not available but is urgently needed, if we are to make an impact on this enormous problem.
Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes
Difficulties with inducing sterile and long lasting protective immunity against malaria with subunit vaccines has renewed interest in vaccinations with attenuated Plasmodium parasites. Immunizations with sporozoites that are attenuated by radiation (RAS) can induce strong protective immunity both in humans and rodent models of malaria.
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
